Scarica l'app Stockscreener
8.35
1.65%
-0.14
Dopo l'orario di chiusura:
8.35
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$8.49
Aprire:
$8.4
Volume 24 ore:
115.06K
Relative Volume:
0.29
Capitalizzazione di mercato:
$434.85M
Reddito:
-
Utile/perdita netta:
$-19.90M
Rapporto P/E:
-15.75
EPS:
-0.53
Flusso di cassa netto:
$-19.80M
1 W Prestazione:
+4.90%
1M Prestazione:
-4.68%
6M Prestazione:
+128.77%
1 anno Prestazione:
+52.93%
Intervallo 1D:
$8.30
$8.6399
Intervallo di 1 settimana:
$7.735
$8.75
Portata 52W:
$3.19
$10.42
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Nome
Diamedica Therapeutics Inc
Settore
Industria
Telefono
(763) 496-5454
Indirizzo
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Confronta DMAC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
8.35 | 442.14M | 0 | -19.90M | -19.80M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-14 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-10-30 | Iniziato | TD Cowen | Buy |
| 2024-10-07 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-24 | Ripresa | Craig Hallum | Buy |
| 2023-06-22 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-04-09 | Iniziato | Oppenheimer | Outperform |
| 2021-02-17 | Iniziato | ROTH Capital | Buy |
| 2020-10-30 | Iniziato | Guggenheim | Buy |
| 2020-07-08 | Iniziato | Maxim Group | Buy |
| 2019-04-30 | Iniziato | Dougherty & Company | Buy |
| 2019-03-05 | Iniziato | Lake Street | Buy |
Mostra tutto
Diamedica Therapeutics Inc Borsa (DMAC) Ultime notizie
What technical charts say about DiaMedica Therapeutics Inc. stockJuly 2025 Action & Free Weekly Watchlist of Top Performers - ulpravda.ru
DiaMedica Therapeutics (DMAC) Seen as Strong Performer with Upco - GuruFocus
DiaMedica Therapeutics sells 1.5 million shares in $12.2 million block trade By Investing.com - Investing.com Nigeria
DiaMedica Therapeutics Raises Capital via Share Offering - TipRanks
DiaMedica Therapeutics sells 1.5 million shares in $12.2 million block trade - Investing.com
A US$59m Drop in the Market Cap of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Is Not What Insiders Like to See After Purchasing Shares Recently - 富途牛牛
DiaMedica Therapeutics (DMAC) price target increased by 25.68% to 15.81 - MSN
Can DiaMedica Therapeutics Inc. stock surprise with earnings upsideTrade Analysis Summary & Growth Focused Stock Pick Reports - Улправда
Craig-Hallum Reaffirms Their Buy Rating on Diamedica Therapeutics (DMAC) - The Globe and Mail
DiaMedica Therapeutics provides DM199 update following FDA meeting - MSN
Why DiaMedica Therapeutics Inc. stock attracts high net worth investorsGold Moves & Low Volatility Stock Suggestions - Улправда
Is DiaMedica Therapeutics Inc. stock in correction or buying zone2025 Market Outlook & Free Low Drawdown Momentum Trade Ideas - Улправда
Aug Big Picture: Why DiaMedica Therapeutics Inc. stock is a value investor pickInsider Selling & Weekly Watchlist for Hot Stocks - Улправда
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
After-Hours Biotech Rally: Inspira, MediciNova, DiaMedica Therapeutics Among Gainers - Nasdaq
DiaMedica (DMAC) Advances with FDA in Preeclampsia Study Plans - GuruFocus
DiaMedica Says FDA Seeks Additional Study Ahead of Pre-IND Submission for Preeclampsia Treatment - marketscreener.com
DiaMedica to conduct additional study for preeclampsia treatment - Investing.com
DiaMedica to conduct additional study for preeclampsia treatment By Investing.com - Investing.com Canada
Diamedica Therapeutics provides DM199 preeclampsia program update - marketscreener.com
DiaMedica Advances DM199 Preeclampsia Program After FDA Pre-IND Meeting - TipRanks
DiaMedica Therapeutics Inc Provides DM199 Preeclampsia Program Update - TradingView — Track All Markets
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA - The AI Journal
[8-K] DiaMedica Therapeutics Inc. Reports Material Event | DMAC SEC FilingForm 8-K - Stock Titan
DiaMedica Therapeutics Earnings Notes - Trefis
DiaMedica Therapeutics (NASDAQ:DMAC) Trading Up 7.4%Here's Why - MarketBeat
DiaMedica Therapeutics Inc (DMAC) Stock News & Articles - 24/7 Wall St.
Top investors say DiaMedica Therapeutics Inc (DMAC) ticks everything they need - setenews.com
DiaMedica Therapeutics (NASDAQ:DMAC) Sets New 1-Year HighTime to Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA) and Diamedica Therapeutics (DMAC) - The Globe and Mail
DiaMedica Therapeutics (NASDAQ:DMAC) Major Shareholder Jan Stahlberg Purchases 182,882 Shares of Stock - Defense World
DiaMedica Therapeutics (NASDAQ:DMAC) Major Shareholder Jan Stahlberg Buys 187,393 Shares of Stock - Defense World
Jan Stahlberg Acquires 208,872 Shares of DiaMedica Therapeutics (NASDAQ:DMAC) Stock - MarketBeat
DiaMedica Therapeutics (NASDAQ:DMAC) Major Shareholder Acquires $1,234,453.50 in Stock - MarketBeat
Insider Buying: DiaMedica Therapeutics (NASDAQ:DMAC) Major Shareholder Purchases 128,426 Shares of Stock - MarketBeat
What dividend safety score for DiaMedica Therapeutics Inc. stock2025 Risk Factors & Fast Gain Stock Tips - Newser
What drives DiaMedica Therapeutics Inc stock priceAnalyst Downgrades & Free Lightning Fast Capital Gains - earlytimes.in
We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth - Yahoo Finance
Private Capital's DiaMedica Therapeutics Inc(DMAC) Holding History - GuruFocus
Why DiaMedica Therapeutics Inc. stock is a value investor pickJuly 2025 Drop Watch & Smart Allocation Stock Tips - moha.gov.vn
There is no way DiaMedica Therapeutics Inc (DMAC) can keep these numbers up - setenews.com
Dir Parsons Acquires 12,000 Of DiaMedica Therapeutics Inc [DMAC] - TradingView
[Form 4] DiaMedica Therapeutics Inc. Insider Trading Activity - Stock Titan
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
DiaMedica In Focus After 52-Week High And FDA Meeting Progress - RTTNews
How DiaMedica Therapeutics Inc. stock compares to industry benchmarksJuly 2025 Intraday Action & Verified Swing Trading Watchlists - newser.com
Diamedica Therapeutics Inc Azioni (DMAC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):